MedTrace Logo

Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients

NCT00759200 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 525

Last updated 2016-11-16

No results posted yet for this study

Summary

This study will evaluate the safety and efficacy of alb-interferon in adults with genotype 2 or 3 chronic hepatitis

Conditions

  • Chronic Hepatitis C

Interventions

DRUG

alb-interferon alfa 2b

900 mcg every 4 weeks

DRUG

alb-interferon alfa 2b

1200 mcg every 4 weeks

DRUG

alb-interferon alfa 2b

1500 mcg every 4 weeks

DRUG

alb-interferon alfa 2b

1800 mcg every 4 weeks

DRUG

peg-interferon

Peg-interferon alfa 2a: 180 mcg 1x per wk.

Sponsors & Collaborators

  • Human Genome Sciences Inc.

    collaborator INDUSTRY

  • Novartis

    lead INDUSTRY

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • Australia
  • Canada
  • France
  • Germany
  • Greece
  • India
  • Italy
  • Poland
  • Spain
  • Taiwan
  • Thailand
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00759200 on ClinicalTrials.gov